Resistance to EGFR Tyrosine Kinase Inhibitor Therapy in Non-Small-Cell Lung Cancer via Newly Acquired Targetable Oncogenic Driver Alterations With an Emphasis on BRAF: Case Series and Literature Review of Treatment

JCO Precis Oncol. 2022 Aug:6:e2100551. doi: 10.1200/PO.21.00551.

Authors

Nicholas P Giustini¹, Sandip Pravin Patel¹, Nathaniel J Myall², José Fernando do Prado Moura³, Amit Kulkarni⁴, Richard C Chao⁵, Heather Wakelee², Lyudmila Bazhenova¹

Affiliations

¹ University of California, San Diego, Moores Cancer Center, La Jolla, CA.
² Stanford University, Stanford, CA.
³ Real Instituto de Oncologia, Recife, Brazil.
⁴ University of Minnesota, Minneapolis, MN.
⁵ Mirati Therapeutics, Inc, San Diego, CA.

PMID: 35952324
DOI: 10.1200/PO.21.00551

No abstract available

Publication types

Review

MeSH terms

Carcinogenesis
Carcinoma, Non-Small-Cell Lung* / drug therapy
ErbB Receptors / genetics
Humans
Lung Neoplasms* / drug therapy
Protein Kinase Inhibitors / therapeutic use
Proto-Oncogene Proteins B-raf / genetics

Substances

Protein Kinase Inhibitors
EGFR protein, human
ErbB Receptors
BRAF protein, human
Proto-Oncogene Proteins B-raf